/ /

  • linkedin
  • Increase Font
  • Sharebar

    Novartis Alcon changes build better platform for ophthalmology


    Patients at core

    Patients remain the backbone of every Novartis Alcon project, Dr. Liew continued. A formal Patient Declaration explicitly lays out the company’s commitment to patients–from improving access to taking the patient perspective in the planning and execution of research and development.

    “The patient perspective guides everything we do, from the types of drugs we develop to taking patient needs and preferences into consideration in designing clinical trials and in designing more effective ways of informing them of trial results,” Dr. Liew pointed out. “Novartis has collaborated with more than 800 patient organizations and we are looking forward to listening to your ideas in the area of glaucoma.”

    Fred Gebhart
    The author is a correspondent for Urology Times, a sister publication.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results